Sarepta Therapeutics Inc (NASDAQ:SRPT) was the target of some unusual options trading on Friday. Investors purchased 22,555 put options on the stock. This represents an increase of approximately 2,651% compared to the typical volume of 820 put options.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the sale, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Douglas S. Ingram bought 38,138 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the transaction, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. Company insiders own 9.60% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its holdings in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 2,493 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Sarepta Therapeutics in the third quarter valued at approximately $204,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Sarepta Therapeutics in the second quarter valued at approximately $206,000. 82.02% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics (SRPT) opened at $61.52 on Monday. The stock has a market capitalization of $3,980.00, a P/E ratio of -30.16 and a beta of 1.37. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics has a twelve month low of $26.26 and a twelve month high of $61.89.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the previous year, the company posted ($0.95) earnings per share. sell-side analysts forecast that Sarepta Therapeutics will post -3.07 EPS for the current year.
Several equities research analysts have recently weighed in on the company. Leerink Swann reissued an “outperform” rating and set a $66.00 target price on shares of Sarepta Therapeutics in a research report on Saturday, September 30th. Instinet reissued a “buy” rating and set a $84.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. reissued a “hold” rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. Finally, Janney Montgomery Scott assumed coverage on Sarepta Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 target price on the stock. Two analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $63.88.
ILLEGAL ACTIVITY WARNING: “Traders Buy High Volume of Sarepta Therapeutics Put Options (SRPT)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/15/traders-buy-high-volume-of-sarepta-therapeutics-put-options-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.